SEARCH:   Advanced

Blood, 15 June 2008, Vol. 111, No. 12, pp. 5672-5682. Prepublished online as a Blood First Edition Paper on April 3, 2008April 10, 2008; DOI 10.1182/blood-2007-09-108175. This Article Full Text (PDF) Supplemental Tables and Figures All Versions of this Article: blood-2007-09-108175v1 blood-2007-09-108175v2 111/12/5672    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Jankovic, D. Articles by Schwaller, J. Search for Related Content PubMed PubMed Citation Articles by Jankovic, D. Articles by Schwaller, J. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted September 4, 2007 Accepted February 23, 2008 Leukemogenic mechanisms and targets of a NUP98/HHEX fusion in acute myeloid leukemia (AML) Dragana Jankovic, Paolo Gorello, Ting Liu, Sabine Ehret, Roberta La Starza, Cecile Desjobert, Florent Baty, Martin Brutsche, Padma-Sheela Jayaraman, Alessandra Santoro, Cristina Mecucci, and Juerg Schwaller* Department of Research, University Hospital Basel, Basel, Switzerland Hematology and Bone marrow transplantation Unit, University of Perugia, Perugia, Italy Department of Biochemistry, University of Bristol, Bristol, United Kingdom Department for Internal Medicine, University Hospital Basel, Basel, Switzerland Division of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom Divisione di Ematologia, Ospedale V. Cervello, Palermo, Italy * Corresponding author; email: j.schwaller{at}unibas.ch. We have studied a patient with acute myeloid leukemia (AML) and t(10;11)(q23;p15) as the sole cytogenetic abnormality. Molecular analysis revealed a translocation involving nucleoporin 98 (NUP98) fused to the DNA binding domain of the hematopoietically expressed homeobox gene (HHEX). Expression of NUP98/HHEX in murine bone marrow cells leads to aberrant self-renewal and a block in normal differentiation which depends on the integrity of the NUP98 GFLG repeats and the HHEX homeodomain. Transplantation of bone marrow cells expressing NUP98/HHEX leads to transplantable acute leukemia characterized by extensive infiltration of leukemic blasts expressing myeloid markers (Gr1+) as well as markers of the B-cell lineage (B220+). A latency period of 9 months and its oligoclonal character suggest that NUP98/HHEX is necessary but not sufficient for disease induction. Expression of EGFP-NUP98/HHEX fusions showed a highly similar nuclear localization pattern as for other NUP98/homeodomain fusions, such as NUP98/HOXA9. Comparative gene expression profiling in primary bone marrow cells provided evidence for the presence of common targets in cells expressing NUP98/HOXA9 or NUP98/HHEX. Some of these genes (Hoxa5, Hoxa9, Flt3) are deregulated in NUP98/HHEX induced murine leukemia as well as in human blasts carrying this fusion and might represent bona fide therapeutic targets. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: Z. Huang, L. C. Dore, Z. Li, S. H. Orkin, G. Feng, S. Lin, and J. D. Crispino GATA-2 Reinforces Megakaryocyte Development in the Absence of GATA-1 Mol. Cell. Biol., September 15, 2009; 29(18): 5168 - 5180. [Abstract] [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020